---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349136"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2026-08-13T20:04:52+00:00"
generated_at: "2026-08-13T20:06:11.029014+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q2 2026 revenue down 17.5% to $3.0M; adjusted EBITDA turns negative

## Summary
- Revenue $3.0M, down 17.5% YoY from $3.6M; gross margin 48.6% vs 50.9% prior year.
- Operating loss widened to $0.3M from $0.1M; adjusted EBITDA turned negative at -$0.1M vs +$0.1M.
- Cash balance $0.3M; operating expenses cut 11.3% YoY to $1.7M.
- 44% of net revenue from new products launched since Jan 2023; 52 new products launched; launched PlusHLTH.com e-commerce.
- U.S. Senate voted 61-32 on H.R. 6500 delaying restrictive hemp-derived cannabinoid provisions.

## SEC filing metadata
- accession: 0001193125-26-349136
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2026-08-13T20:04:52+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/0001193125-26-349136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/cvsi-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349136
- JSON: https://secwatch.observer/filing/0001193125-26-349136.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.